Ashton Thomas Private Wealth LLC Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Ashton Thomas Private Wealth LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 30.8% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 57,958 shares of the biopharmaceutical company's stock after selling 25,833 shares during the quarter. Ashton Thomas Private Wealth LLC's holdings in Pfizer were worth $1,677,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in PFE. China Universal Asset Management Co. Ltd. purchased a new stake in Pfizer in the 1st quarter worth approximately $315,000. GSA Capital Partners LLP purchased a new position in Pfizer during the 1st quarter valued at about $439,000. Koshinski Asset Management Inc. boosted its stake in Pfizer by 20.5% in the first quarter. Koshinski Asset Management Inc. now owns 24,265 shares of the biopharmaceutical company's stock valued at $673,000 after acquiring an additional 4,130 shares in the last quarter. Dearborn Partners LLC increased its holdings in shares of Pfizer by 18.4% in the first quarter. Dearborn Partners LLC now owns 32,683 shares of the biopharmaceutical company's stock valued at $907,000 after purchasing an additional 5,077 shares during the period. Finally, Private Management Group Inc. grew its position in Pfizer by 270.7% during the first quarter. Private Management Group Inc. now owns 26,579 shares of the biopharmaceutical company's stock valued at $738,000 after buying an additional 19,409 shares during the period. Institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Sanford C. Bernstein initiated coverage on Pfizer in a research note on Thursday, October 17th. They issued a "market perform" rating and a $32.00 price objective for the company. Citigroup assumed coverage on Pfizer in a research note on Friday, October 25th. They set a "neutral" rating and a $30.00 price objective on the stock. Evercore ISI upgraded Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. UBS Group lifted their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 31st. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Eight investment analysts have rated the stock with a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $33.58.

Pfizer Stock Up 2.0 %

Shares of NYSE PFE traded up $0.53 during trading on Wednesday, reaching $26.72. 47,944,807 shares of the stock were exchanged, compared to its average volume of 37,776,984. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $31.54. The business's 50-day moving average price is $28.80 and its 200 day moving average price is $28.68. The company has a market capitalization of $151.42 billion, a price-to-earnings ratio of 35.54, a price-to-earnings-growth ratio of 0.83 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analysts' expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business's revenue for the quarter was up 31.2% on a year-over-year basis. During the same period last year, the company posted ($0.17) earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.29%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer's dividend payout ratio is currently 227.03%.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company's stock, valued at approximately $282,400. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.